Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694392 · ClinicalTrials.gov registry record
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
A clinical trial, sponsored by Kaiser Permanente.
- Completed
- Registry status
- 2,776,278
- Enrollment target
NCT03694392 is a clinical trial that has completed, run by Kaiser Permanente. The registered enrollment target is 2,776,278 participants.
The verdict
NCT03694392 has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- 2,776,278 participants
- Enrollment target
Study Summary
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age. During this study, Flublok Quadrivalent or SD-IIV will be administered according to the guidelines in the Prescribing Information materials and only to persons for whom it is indicated. The 2018-2019, 2019-2020, and 2020-2021 formulations of recombinant influenza vaccine (Flublok Quadrivalent vaccine) and SD-IIV will be evaluated for outcomes including all polymerase chain reaction (PCR)-confirmed influenza, PCR-confirmed hospitalized influenza, hospitalized community-acquired pneumonia and cardio-respiratory events.
Interventions
- BIOLOGICAL Flublok Quadrivalent
- BIOLOGICAL Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,776,278 participants |
| Start Date | 2018-09-16 |
| Est. Completion | 2022-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694392
The ClinicalTrials.gov registry entry for NCT03694392 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,776,278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flublok Quadrivalent is the first listed.
NCT03694392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03694392 about?
NCT03694392 is a clinical study titled "Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years". The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age. During this study, Flublok Quadrivalent or SD-IIV will be administered according to the guidelin...
What is the current status of trial NCT03694392?
This trial is currently completed. The enrollment target is 2,776,278 participants. The study started on 2018-09-16. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03694392?
The interventions under investigation include: Flublok Quadrivalent (BIOLOGICAL), Standard Dose Inactivated Influenza Vaccine (SD-IIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03694392?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.